A new collaborative study coordinated by LMU/SyNergy investigators and the University of Vienna proposes a novel clinical workflow for the reliable biomarker-based identification of amyloid pathology in memory clinic patients, in preparation of disease-modifying treatments against Alzheimer’s disease